# Tanezumab In Osteoarthritis Of The Knee (2)

> **NCT00830063** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 832 (actual)

## Conditions studied

- Arthritis
- Osteoarthritis

## Interventions

- **BIOLOGICAL:** tanezumab 10 mg
- **BIOLOGICAL:** tanezumab 5 mg
- **DRUG:** naproxen
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00830063
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-05
- **Primary completion:** 2010-05-17
- **Final completion:** 2010-08-31
- **Target enrollment:** 832 (ACTUAL)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00830063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00830063, "Tanezumab In Osteoarthritis Of The Knee (2)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00830063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*